American Biogenetic Sciences presents Solfib data at Society of Thrombosis and Haemostasis (STH):
This article was originally published in Clinica
American Biogenetic Sciences' says Solfib its soluble fibrinogen assay is an excellent rule-out test for MI and can identify patients at risk of post-operative thrombosis. The soluble fibrinogen antibody could also be used to deliver thrombolytics, according to data presented at the International Society of Thrombosis and Haemostasis' annual congress (Jerusalem, June 11th-16th). The negative predictive value for MI is 100%, according to data presented by ABS president Dr Paul Gargan. He described the MI rule-out finding highly significant - because of the potential cost savings. Only 15% of patients who are assessed for chest pain actually have MI.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.